Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
- 1 November 1996
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 101 (5), 488-501
- https://doi.org/10.1016/s0002-9343(96)00282-3
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelingThe American Journal of Medicine, 1995
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994
- Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical propertiesCalcified Tissue International, 1993
- Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis.BMJ, 1993
- Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitoninOsteoporosis International, 1993
- Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal womenOsteoporosis International, 1993
- Preclinical pharmacology of alendronateOsteoporosis International, 1993
- Involutional OsteoporosisNew England Journal of Medicine, 1986
- Etidronate disodium in postmenopausal osteoporosisClinical Pharmacology & Therapeutics, 1976